CONTENTS:
- Benzodiazepines: the time for systematic change is now [Editorial]. Schmitz A., p. 219-221.
- Assessing New Zealand's Cannabis Legalization and Control Bill: prospects and challenges [Addiction Opinion and Debate]. Wilkins C., Rychert M., p. 222-230.
- Legal cannabis - what's in it? Cousijn J., p. 231-232.
- Minimum THC unit pricing: an opportunity for harm reduction. Freeman T.P., Lynskey M.T., p. 232-233.
- Regulating cannabis retail for public health over private profit. Lenton S., p. 233-235.
- Acknowledging and monitoring the costs of seriously regulating cannabis. Smart R., p. 235-236.
- The rejection of cannabis legalization in New Zealand: issues with the Cannabis Legalization and Control Bill or wider concerns? Wilkins C., Rychert M., p. 236-238.
- Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. Taylor L., Claire R., Campbell K., Coleman-Haynes T., Leonardi-Bee J., Chamberlain C., et al., p. 239-277.
- Commentary on Taylor et al. : Nicotine replacement therapy in pregnancy-amalgamating and contextualising evidence from different study designs. Hartmann-Boyce J., Lindson N., p. 278-279.
- Estimated televised alcohol advertising exposure in the past year and associations with past 30-day drinking behavior among American adults: results from a secondary analysis of large-scale advertising and survey data. Niederdeppe J., Avery R.J., Tabor E., Lee N.W., Welch B., Skurka C., p. 280-289.
- Commentary on Niederdeppe et al. : Alcohol marketing exposure regulation should apply to all. Goldnadel Monteiro M., p. 290-291.
- Alcohol use and cognitive functioning in young adults: improving causal inference. Mahedy L., Suddell S., Skirrow C., Fernandes G.S., Field M., Heron J., et al., p. 292-302.
- Commentary on Mahedy et al. : Cognitive impairments and heavy drinking - a hallmark of vulnerable groups. Peeters M., Vollebergh W., p. 303-304.
- A randomized clinical trial of a group cognitive-behavioral therapy to reduce alcohol use among human immunodeficiency virus-infected outpatients in western Kenya. Papas R.K., Gakinya B.N., Mwaniki M.M., Lee H., Keter A.K., Martino S., et al., p. 305-318.
- Methadone-related deaths among youth and young adults in Sweden 2006-15. Fugelstad A., Bremberg S., Hjelmström P., Thiblin I., p. 319-327.
- Prevalence and correlates of receptive syringe-sharing among people who inject drugs in rural Appalachia. White R.H., O'Rourke A., Kilkenny M.E., Schneider K.E., Weir B.W., Grieb S.M., et al., p. 328-336.
- Commentary on Hamilton White et al. : Receptive syringe-sharing among people who inject drugs in rural settings. Iversen J., Maher L., p. 337-338.
- Characteristics and circumstances of death related to the self-administration of ketamine. Darke S., Duflou J., Farrell M., Peacock A., Lappin J., p. 339-345.
- Comparison between success rates for smokers re-treated by a smokers' clinic and success rates for smokers treated for the first time. Stepankova L., Kralikova E., Zvolska K., Pankova A., Adamcekova Z., Kuhn M., et al., p. 346-355.
- Commentary on Stepankova et al. : Try, try, try again-smoking cessation clinics and their role in the cessation journey. Chaiton M., p. 356-357.
- Prevalence and correlates of receipt by smokers of general practitioner advice on smoking cessation in England: a cross-sectional survey of adults. Jackson S.E., Garnett C., Brown J., p. 358-372.
- The effectiveness of an indicated prevention programme for substance use in individuals with mild intellectual disabilities and borderline intellectual functioning: results of a quasi-experimental study. Schijven E.P., Hulsmans D.H.G., VanDerNagel J.E.L., Lammers J., Otten R., Poelen E.A.P., p. 373-381.
- Developmental patterns of tobacco product and cannabis use initiation in high school. Cho J., Goldenson N.I., Kirkpatrick M.G., Barrington-Trimis J.L., Pang R.D., Leventhal A.M., p. 382-393.
- Perceived safety of smoking a few cigarettes during pregnancy and provider advice in a sample of pregnant smokers from Romania. Jaber R., Blaga O.M., Dascal M.D., Meghea C.I., p. 394-399.
- Bidirectional effects between loneliness, smoking and alcohol use: evidence from a Mendelian randomization study. Wootton R.E., Greenstone H.S.R., Abdellaoui A., Denys D., Verweij K.J.H., Munafo M.R., et al., p. 400-406.
- The Pub and the People. A Worktown Study by Mass Observation. MacGregor S., p. 407-411.
- Evaluating the effectiveness of the smartphone app, Drink Less, compared with the NHS alcohol advice webpage, for the reduction of alcohol consumption among hazardous and harmful adult drinkers in the UK at 6-month follow-up: protocol for a randomised controlled trial. Garnett C., Oldham M., Angus C., Beard E., Burton R., Field M., et al., p. 412-425.
- Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. Roberts J., White B., Attalla D., Ward S., Dunlop A.J., p. 426-427.
- Integrating episodes of imprisonment and the cascade of care for opioid use disorder. Cossar R.D., Stewart A.C., Winter R., Curtis M., Dietze P.M., Ogloff J.R.P., et al., p. 427-428.
- Effects of moderate alcohol consumption on subclinical femoral atherosclerosis in smokers and non-smokers. Ugusman A., Mohamed I.N., Mohamed Pakri Mohamed R., Kumar J., p. 428-429.
- Commentary on Jin et al. (2020): Expanding the impact of opioid agonist therapy for opioid use disorder-are there lessons from the HIV/AIDS response? Klimas J., Wood E., McCracken R., p. 429-430.